Language Select
瓦里安標誌

Press Releases

2019年 05月 16日
Varian (NYSE: VAR) today announced preliminary estimates of the incremental gross impact of new tariffs. Over the past week, the US increased tariffs on certain goods (US List 3), and imposed new... Read more
2019年 05月 13日
At a ceremony in Singapore today, Varian (NYSE: VAR) announced, in partnership with Proton Therapy Pte., Ltd, the completion of the cyclotron installation for the Varian ProBeam® Compact... Read more
2019年 05月 13日
Varian (NYSE: VAR) today announced it was selected by Port Moresby General Hospital (PMGH) in Papua New Guinea to equip its cancer treatment center with the Halcyon™ radiotherapy system, as well... Read more
2019年 05月 09日
Acquisition Key Highlights The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart. Early positive clinical evidence suggests that... Read more
2019年 05月 09日
Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian (NYSE: VAR) was selected to equip two proton therapy centers in Norway with the ProBeam®... Read more
2019年 05月 09日
Varian (NYSE: VAR) today announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research. The... Read more
2019年 05月 07日
Varian (NYSE: VAR) today announced that it will be attending the UBS Global Healthcare Conference (May 20-22) and the 2019 RBC Capital Markets Healthcare Conference (May 21-22) in New York City.... Read more
2019年 04月 30日
Varian (NYSE: VAR) announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate (HDR) brachytherapy treatments with the Bravos™... Read more
2019年 04月 29日
Varian (NYSE: VAR) today announced Ofuna Chuo Hospital, Kamakura City, Kanagawa Prefecture, Japan is the first clinic in the country to begin treating cancer patients using the Halcyon™... Read more
2019年 04月 26日
Bringing together a global community of clinicians and scientists from leading cancer clinics to develop best practices for adaptive radiotherapy based on clinical evidence, Varian (NYSE: VAR)... Read more

Corporate Communications Contact

Mark Plungy
Director, Public Relations
650.424.5630
mark.plungy@varian.com

Investor Relations Contact

Mike Bruff
SVP, Investor Relations
650.424.5163
investors@varian.com